Full Judgment Text
Text read from the judgment PDF published on the High Court's eCourts portal, through the
Indian High Court Judgments open data set (Dattam Labs,
CC BY 4.0).
The court's own copy is the authoritative text.
*
IN THE HIGH COURT OF DELHI AT NEW DELHI
%
+
Judgment delivered on: 28.03.2026
C.A.(COMM.IPD-PAT) 493/2022
PRESIDENT AND FELLOWS OF HARVARD
COLLEGE
.....Appellant
versus
CONTROLLER GENERAL OF PATENTS DESIGNS AND
TRADEMARKS
.....Respondent
Advocates who appeared in this case
For the Appellant
:
Dr. Satyapal Arora, Mr. Ashish Sharma, Mr.
Kuldeep Kumar Singh & Mr. Nitin Sharma,
Advocates.
For the Respondent :
Mr. Balendu Shekhar, CGSC with Mr.
Krishna Chaitanya, Mr. Rajkumar Maurya,
Mr. Divyansh Singh Dev and Ms. Tanisha
Samanta, Advocates.
Dr. Bhanumathi R, Assistant Controller of
Patents & Designs (through VC).
CORAM:
HON'BLE MR. JUSTICE TEJAS KARIA
JUDGMENT
TEJAS KARIA, J
INTRODUCTION
1.
This is an Appeal under Section 117 of the Patents Act, 1970 (“Act”)
read with Section 151 of the Code of Civil Procedure, 1908 filed against the
Signed By:NEELAM
SHARMA
17:52:11
C.A.(COMM.IPD-PAT) 493/2022
order dated 25.08.2022 (“Impugned Order”) passed by the Controller
General of Patents, Designs and Trademarks (“Respondent / Controller”)
whereby the learned Controller refused the grant of patent vide Patent
Application
No.
201617000758
titled
as
“SC-β
CELLS
AND
COMPOSITIONS AND METHODS FOR GENERATING THE SAME” dated
08.01.2016 (“Subject Application”).
FACTUAL MATRIX
2.
On 11.06.2013, the Appellant filed the First Priority Application
corresponding to the Subject Application vide Application No. US
61/833,898. On 28.03.2014, the Appellant filed the Second Priority
Application corresponding to the Subject Application vide Application No.
US 61/972,272. On 11.06.2014, the Appellant filed the Patent Cooperation
Treaty Application corresponding to the Subject Application vide
Application
No.
PCT/US2014/041992
(“PCT
Application”).
On
08.01.2026, the Appellant filed the Subject Application.
3.
On 08.01.2016, the Appellant filed Form No. 13 for amendments in
the claims as PCT Application had 1 claim, while the Subject Application is
filed with 29 claims. On 01.06.2017, the Appellant filed a request for
examination and voluntarily amended the claims. Thereafter, the Respondent
issued the First Examination Report dated 28.02.2020 (“FER”). The
Appellant filed the response to the FER along with the amended claims and
Form No. 13 for voluntary amendment in claims with respect to the PCT
Application on 28.08.2020 (“Reply”).
4.
The Respondent issued a hearing notice dated 24.11.2020 scheduling
the hearing for 08.01.2021. A request for adjournment under Rule 129 of the
Patent Rules, 2003 was filed for the hearing scheduled on 08.01.2021. An
Signed By:NEELAM
SHARMA
17:52:11
C.A.(COMM.IPD-PAT) 493/2022
extended hearing notice was issued on 09.06.2021 for a hearing scheduled
for 08.07.2021. Subsequently, an extended hearing notice was issued on
25.06.2021 (“Hearing Notice”) for a hearing scheduled for 06.08.2021
(“Hearing”). On 21.08.2021, written submissions were filed on the basis of
the oral arguments submitted in the Hearing by the Appellant along with the
amended claims (“Written Submissions”).
5.
Vide the Impugned Order, the Respondent refused the Subject
Application under Section 15 of the Act stating that the Subject Application
does not meet the requirement under Sections 3(j), 3(e), 10(4) and 10(5) of
the Act.
SUBMISSIONS ON BEHALF OF THE APPELLANT
6.
The learned Counsel for the Appellant made the following
submissions:
6.1.
The Respondent has refused the Subject Application on the
following grounds for the objections raised in the Hearing Notice:
(i) definitiveness under Section 10(4) and Section 10(5) of the Act;
(ii) non-patentability under Sections 3(j) and 3(e) of the Act; and
(iii) sufficiency of disclosure under Section 10 (4) of the Act.
6.2.
The Respondent acknowledges that claim no. 1 recites a
composition comprising a non-native pancreatic beta (“β”) cell and
one or more pharmaceutically acceptable carriers, additives, and /
or diluents. The Respondent has refused the Subject Application on
the ground that the cells allegedly are defined by a broad generic
gene expression profile and that the phrase ‘non-native’, ‘native’,
and ‘gene expression profile’ are unclear. Thus, the claims
Signed By:NEELAM
SHARMA
17:52:11
C.A.(COMM.IPD-PAT) 493/2022
allegedly are not definitive as required under Section 10(4)(a) of
the Act.
6.3.
For interpretation of words in claims, first priority is to take help of
intrinsic evidence, i.e., from patent documents, specifications etc.
Therefore, for true meaning of words in the claim, first of all
specifications are to be looked into. The word ‘non-native’ cells are
well defined in the specifications. The relevant paragraphs from
the Complete Specification of the PCT Application are reproduced
hereunder:
“[193] The SC-β cells disclosed herein share many
distinguishing features of native β cells, but are different
in certain aspects (e.g., gene expression profiles). In
some embodiments, the SC-β cell is non-native. As used
herein, “non-native” means that the SC-β cells are
markedly different in certain aspects from β cells which
exist in nature, i.e., native β cells. It should be
appreciated, however, that these marked differences
typically pertain to structural features which may result
in the SC-β cells exhibiting certain functional
differences, e.g., although the gene expression patterns
of SC-β cells differs from native β cells, the SC-β cells
behave in a similar manner to native β cells but certain
functions may be altered (e.g., improved) compared to
native β cells.
*** *** ***
[329] Aspects of the disclosure involve generating SC-β
cells which resemble endogenous mature β cells in form
and function, but nevertheless are distinct from native β
cells.
*** *** ***
[597] The generation of insulin-producing pancreatic β
cells from stem cells in vitro would provide an
unprecedented cell source for drug discovery and cell
transplantation therapy in diabetes.”
Signed By:NEELAM
SHARMA
17:52:11
C.A.(COMM.IPD-PAT) 493/2022
6.4.
These ‘non-native’ cells are novel and inventive and do not occur
in nature. However, the native pancreatic β cells are obtained from
natural sources and cannot be reliably grown in vitro. In contrast,
non-native pancreatic β cells can be reliably generated in vitro
from stem cells or precursors to the non-native pancreatic β cells
using protocols such as those described in the Subject Application.
6.5.
Regarding input source for generating ‘non-native’ cells, the
Subject Application describes numerous examples of cells that
could be used to make non-native pancreatic β cells and do not
necessarily involve the destruction of embryo cells. In some
embodiments, the source of human stem cells or pluripotent stem
cells used for chemically induced differentiation into mature,
insulin positive cells did not involve destroying a human embryo.
6.6.
The pending claims recite a composition comprising a non-native
pancreatic β cell and one or more pharmaceutically acceptable
carriers, additives, and / or diluents and the relevant paragraphs
from the Complete Specification is reproduced hereunder:
“[511]
For administration to a subject, a cell
population produced by the methods as disclosed herein,
e.g. a population of SC-β cells (produced by contacting at
least one insulin-positive endocrine cell with at least one p
cell maturation factor (e.g., any one, two, three, four, five,
or more p cell maturation factors as described herein) can
be administered to a subject, for example in
pharmaceutically acceptable compositions. These
pharmaceutically acceptable compositions comprise a
therapeutically-effective amount a population of SC-β
cells as described above, formulated together with one or
more pharmaceutically acceptable carriers (additives)
and/or diluents.
*** *** ***
Signed By:NEELAM
SHARMA
17:52:11
C.A.(COMM.IPD-PAT) 493/2022
[563]
Pharmaceutical compositions comprising
effective amounts of a population of SC-β cells are also
contemplated by the present invention. These
compositions comprise an effective number of SC-β cells,
optionally, in combination with a pharmaceutically
acceptable carrier, additive or excipient. In certain
aspects of the present invention, a population of SC-β cells
are administered to the subject in need of a transplant in
sterile saline. In other aspects of the present invention, a
population of SC-β cells are administered in Hanks
Balanced Salt Solution (HBSS) or Isolyte S, pH 7.4. Other
approaches may also be used, including the use of serum
free cellular media. In one embodiment, a population of
SC-β cells are administered in plasma or fetal bovine
serum, and DMSO. Systemic administration of a
population of SC-β cells to the subject may be preferred in
certain indications, whereas direct administration at the
site of or in proximity to the diseased and/or damaged
tissue may be preferred in other indications.”
6.7.
The carrier is selected so as to be compatible with other aspects of
the composition, including the delivery of the non-native
pancreatic β cells to a subject. This claimed ‘non-native’ cells
composition does not fall under non-patentable subject matter
under Section 3(j) of the Act. The relevant paragraphs from the
Complete Specification of the PCT Application is reproduced
hereunder:
“[514] As used here, the term “pharmaceuticallyacceptable carrier” means a pharmaceutically-acceptable
material, composition or vehicle, such as a liquid or solid
filler, diluent, excipient, manufacturing aid (e.g., lubricant,
talc magnesium, calcium or zinc stearate, or steric acid),
or solvent encapsulating material, involved in carrying or
transporting the subject compound from one organ, or
portion of the body, to another organ, or portion of the
body. Each carrier must be “acceptable” in the sense of
being compatible with the other ingredients of the
formulation and not injurious to the patient. Some
Signed By:NEELAM
SHARMA
17:52:11
C.A.(COMM.IPD-PAT) 493/2022
examples of materials which can serve as
pharmaceutically-acceptable carriers include: (1) sugars,
such as lactose, glucose and sucrose; (2) starches, such as
corn starch and potato starch; (3) cellulose, and its
derivatives, such as sodium carboxymethyl cellulose,
methylcellulose, ethyl cellulose, microcrystalline cellulose
and cellulose acetate; (4) powdered tragacanth; (5) malt;
(6) gelatin; (7) lubricating agents, such as magnesium
stearate, sodium lauryl sulfate and talc; (8) excipients,
such as cocoa butter and suppository waxes; (9) oils, such
as peanut oil, cottonseed oil, safflower oil , sesame oil,
olive oil, corn oil and soybean oil; (10) glycols, such as
propylene glycol; (11) polyols, such as glycerin, sorbitol,
mannitol and polyethylene glycol (PEG); (12) esters, such
as ethyl oleate and ethyl laurate; (13) agar; (14) buffering
agents, such as magnesium hydroxide and aluminum
hydroxide; (15) alginic acid; (16) pyrogen-free water; (17)
isotonic saline; (18) Ringer's solution; (19) ethyl alcohol;
(20) pH buffered solutions; (21) polyesters, polycarbonates
and/or polyanhydrides; (22) bulking agents, such as
polypeptides and amino acids (23) serum component, such
as serum albumin, HDL and LDL; (22) C2-C12 alcohols,
such as ethanol; and (23) other non-toxic compatible
substances employed in pharmaceutical formulations.
Wetting agents, coloring agents, release agents, coating
agents, sweetening agents, flavoring agents, perfuming
agents, preservative and antioxidants can also be present
in the formulation. The terms such as “excipient”,
“carrier”, “pharmaceutically acceptable carrier” or the
like are used interchangeably herein.
*** *** ***
[551] In some embodiments, a population of SC-β cells as
disclosed herein can be supplied in the form of a
pharmaceutical composition, comprising an isotonic
excipient prepared under sufficiently sterile conditions for
human administration. For general principles in medicinal
formulation, the reader is referred to Cell Therapy: Stem
Cell Transplantation, Gene Therapy, and Cellular
Immunotherapy, by G. Morstyn & W. Sheridan eds,
Cambridge University Press, 1996; and Hematopoietic
Stem Cell Therapy, E. D. Ball, J. Lister & P. Law, Churchill
Signed By:NEELAM
SHARMA
17:52:11
C.A.(COMM.IPD-PAT) 493/2022
Livingstone, 2000. Choice of the cellular excipient and any
accompanying elements of the composition comprising a
population of SC-β cells as disclosed herein will be
adapted in accordance with the route and device used for
administration. In some embodiments, a composition
comprising a population of SC-β cells can also comprise or
be accompanied with one or more other ingredients that
facilitate the engraftment or functional mobilization of the
SC-β cells. Suitable ingredients include matrix proteins
that support or promote adhesion of the SC-β cells, or
complementary cell types, especially endothelial cells. In
another embodiment, the composition may comprise
resorbable or biodegradable matrix scaffolds.”
6.8.
There may be a number of such cases, where such type of cells or
their compositions have been granted patent in India. One example
is the grant of Patent No. 404415 granted on 24.08.2022 in Indian
Patent Application No. 1616/DELNP/2015. The applicant as
referred to the principal claim no. 1 of the aforesaid patent.
6.9.
On further observing the prosecution history in the Indian Patent
Office, it is found that the patentee has indicated that in the written
submissions on Page No. 1 that cell preparation means a
composition. The relevant paragraph of the written submissions is
reproduced hereunder:
“claim 1 has been amended to claim a cell preparation
which is a composition comprising of pluripotent stem
cells and DMSO and/or serum albumin, as supported by
paragraph [0026] of English specification.”
On further analysis of the source of stem cells, as claimed in claim
no. 1, the specification states that the English translation on Page
No. 16 of specification describes about the said pluripotent stem
cells
called
Multilineage
differentiating
Stress
Enduring
(“MUSE”) cells.
Signed By:NEELAM
SHARMA
17:52:11
C.A.(COMM.IPD-PAT) 493/2022
6.10. The abovementioned example draws similarity with the Subject
Application of the Appellant as: (i) the source of stem cells is plant
or animal in whole or part thereof; and (ii) the claims relate to cell
preparation or cell composition. The Subject Application has
further characteristics that though the source was cells from human
/ animal body, these cells were processed and generated to get nonnative β cell. These non-native β cell are not occurring in nature
and are distinct from natural occurring native β cells. The nonnative β cell of the present invention have been novel and
inventive and the claimed composition of involving non-native β
cells has synergic effect, and have pharmaceutical efficacy and
solves the long-standing problem of the prior art. The present
invention solves the technical problem of the prior art and relates
to a patentable subject matter and is not hit by Section 3(j) of the
Act.
6.11. The stem cell derived β (“SC-β”) cells were generated by
engineering an elaborate process and cannot be said to be a part of
an animal in whole or part thereof and the claims are not hit by
Section 3(j) of the Act. Reliance was placed upon the decision in
Imclone LLC v. Assistant Controller of Patents and Designs,
Government of India, 2024 SCC OnLine Mad 8397 wherein the
Court held that the antibody was generated by deleting murine
genetic material from mice and replacing the same with human
genetic material in the mice and, thereafter, injecting an engineered
antigen into the mice. After doing so, material extracted from the
spleen of the mice was fused with myeloma cells by the hybridoma
Signed By:NEELAM
SHARMA
17:52:11
C.A.(COMM.IPD-PAT) 493/2022
process. This resulted in the antibody over which the patent claim
is made.
6.12. Non-native SC-β cells, like tri-hybrid cells, involve technical
human intervention and are, therefore, patentable. SC-β cells are
novel and inventive and do not form part of animal or plant and are
not hit by Section 3(i) of the Act. Non-native SC-β cells are novel
and inventive comparable to tri-hybrid cells; both are man-made,
not naturally occurring, not plant / animal parts, and not from an
essentially biological process. Reliance was placed upon the
decision
in
BTS
Research
International
Pty.
Ltd.
(SR/55/2020/PT/KOL) v. The Controller General of Patents &
Designs, Mumbai & Ors., 2025 SCC OnLine Cal 2943 wherein
the Court held that Section 3(j) of the Act exclusion must be
narrowly construed; inventions involving genetic engineering or
non-natural cell creation are not hit by Section 3(j) of the Act. The
Court recognized tri-hybrid cells as outside Section 3(j) of the Act,
setting a precedent that applies similarly to SC-β cells.
6.13. In the decision of Natural Alternatives International, Inc. v.
Creative Compounds LLC, 918 F.3d 1338 (2019) wherein the
Court held that compositions comprising a component of natural
origin are patentable, so long as the composition demonstrates
different characteristics when compared to the component found in
nature.
6.14. There are corresponding applications, main, divisional or
continuation in part applications have been granted patent in the
United States of America, Great Britain, Australia, Germany,
Signed By:NEELAM
SHARMA
17:52:11
C.A.(COMM.IPD-PAT) 493/2022
Japan, Korea, Russia etc. The Appellant filed 29 identical claims
for examination, which were granted patent in the United
Kingdom.
6.15. Accordingly, the present Appeal shall be allowed, and the
Impugned Order is liable to be set aside.
SUBMISSIONS ON BEHALF OF THE RESPONDENT
7.
The learned Counsel for the Respondent made the following
submissions:
7.1.
Section 3(j) of the Act based on Article 27.3(b) of the TradeRelated Aspects of Intellectual Property Rights Agreement states
“Plants and animals in whole or any parts thereof other than
micro-organisms but including seeds, varieties and species and
essentially biological processes for production and propagation of
plants and animals.” are not patentable.
7.2.
The only exception appears to be microorganisms which may be
granted a patent. However, when a microorganism which has been
just isolated from nature, is not considered to be patentable under
Section 3(c) of the Act. Section 3(c) of the Act prohibits
patentability of “the mere discovery of a scientific principle or the
formulation of an abstract theory or discovery of any living thing
or non-living substance occurring in nature”. Hence, the
microorganism, which are patentable are limited to those that are
genetically modified organisms only.
7.3.
Section 3(j) under the Act, expressly excludes “plants and animals
in whole or any part thereof” irrespective of whether those parts
are cultured, maintained, or differentiated in vitro. Accepting the
Signed By:NEELAM
SHARMA
17:52:11
C.A.(COMM.IPD-PAT) 493/2022
Appellant’s contention that such cells are ‘synthetic’ would create
a loophole whereby any naturally derived biological material could
be rebranded as synthetic simply by laboratory handling. The
distinction between isolation or differentiation of natural material
and genuine synthetic constructs has also been recognized
internationally in the decision of Association for Molecular
Pathology et al. v. Myriad Genetics Inc. et al., 2013 SCC OnLine
US SC 47 wherein the Court held that where naturally occurring
deoxyribonucleic acid (“DNA”) was held unpatentable, while truly
synthetic complementary DNA (“cDNA”) was treated differently.
Applying that principle, the claimed SC-β cells, however cultured,
remain natural derivatives and fall squarely within the exclusion of
Section 3(j) of the Act.
7.4.
Microbes are single-celled organisms. Animal is a name reserved
for a multicellular eukaryote that is heterotrophic, so organisms
that are bigger than a single cell and almost all their cells have a
nucleus. A genetically modified human or plant cell cannot be
equated to a genetically modified microbe because it falls under
Section 3(j) of the Act. Section 3(j) of the Act prohibits
patentability of an animal and plant in whole.
7.5.
‘Native’ cell means a cell that is found in a natural setting, which
includes multicellular organism cells in vivo i.e., part of an
organism, and unicellular organisms ‘in environment’ i.e., part of a
natural environment. In biology, native cells are usually considered
to be cells that are naturally found in an organism or environment,
as opposed to cells that have been introduced artificially.
Signed By:NEELAM
SHARMA
17:52:11
C.A.(COMM.IPD-PAT) 493/2022
7.6.
In the Subject Application ‘non-native’ cells are cells isolated from
the human body for use in human itself. They, however, do not
have a comparison of non-nativeness. In the Subject Application,
the definition of “non-native pancreatic β cell” fails to define what
is ‘native’. Without a tangible identity of either ‘non-native’ or
‘native’, it remains unclear what the terms mean with respect to the
present claim of the Appellant. The Appellant to substantiate their
claim has stated that the “gene expression profile” of the claimed
(non-native) SC-β cell is different from native human cells.
7.7.
Taken together, the terminology ‘native’, ‘non-native’ and ‘gene
expression profile that is different’ is unclear because:
a. no standard for ‘native’ or a ‘gene expression profile’ is
defined;
b. there is no such thing as a standard gene expression profile
for a ‘native’ cell, i.e., the standard itself is a variable;
c. it would be an undue burden to test a cell for the ‘non-native’
feature if all ‘native’ gene expression profile variations have
to be taken into account for a comparison; and
d. the gene expression profile of a pancreatic cell to be
‘different’ from a reference cell is also unclear as there is no
support data for such an interpretation.
7.8.
The Subject Application is silent with regard to the specific cell
type, the specific phase when the genes and insulin crystals as
claimed are present or the gene expression level necessary to
obtain the composition.
Signed By:NEELAM
SHARMA
17:52:11
C.A.(COMM.IPD-PAT) 493/2022
7.9.
The “Summary of the Invention” in the Complete Specification of
the PCT Application also states non-native pancreatic β “cell is not
genetically modified”, meaning it can be natural cell isolated from
human. The Appellant has placed reliance upon Paragraph Nos.
[4], [201] and [202] of the Complete Specification of the PCT
Application. The reliance on foreign grants or international
practice is misplaced as Indian patent jurisprudence has
consistently applied a stricter construction of Section 3(j) of the
Act, particularly in relation to human embryonic stem cells, on
grounds of both express statutory exclusion and the legislative
intent which was to categorically exclude human/animal parts and
embryonic material from patentability, irrespective of their
potential utility in regenerative medicine.
7.10. The Appellant’s reliance on BTS Research International (supra)
is misplaced as in the said case, the Court considered tri-hybrid
chimeric cells produced through fusion of three distinct somatic
cells (human and mouse), a construct that does not and cannot
exist in nature. It was held that such a creation involved a level of
artificial genetic manipulation that took it outside the scope of
Section 3(j) of the Act. The Subject Application concerns SC-β
cells. It is true that in vitro differentiation relies on specialized
culture media and laboratory conditions, which are not a direct
‘replication’ of what occurs within the body. However, the critical
point is that despite differences in the environment that induces
differentiation, the ultimate product is biologically identical to the
β cells that naturally arise in vivo and, thereby, are biological
Signed By:NEELAM
SHARMA
17:52:11
C.A.(COMM.IPD-PAT) 493/2022
derivatives of natural origin (human or animal material). The
laboratory process merely triggers a natural developmental
pathway inherent in stem cells; it does not give rise to a novel
product unknown to nature.
7.11. Accordingly, the Impugned Order is liable to be upheld, and the
present Appeal be dismissed.
REJOINDER SUBMISSIONS ON BEHALF OF THE APPELLANT
8.
The learned Counsel for the Appellant made the following rejoinder
submissions:
8.1.
The Respondent seeks to equate the Appellant’s SC-β cells with
naturally occurring pancreatic β cells. This characterization is
erroneous. The non-native SC-β cells claimed are structurally,
functionally, and genetically distinct from native β cells. They
exhibit altered gene expression profiles, enhanced glucose
responsiveness, and mono-hormonal features that are not found in
nature. Thus, the present invention is not a mere product of nature
but the outcome of deliberate human technical intervention.
8.2.
The Respondent attempts to distinguish the BTS Research
International (supra) on grounds that tri-hybrid cells were wholly
unnatural, whereas SC-β cells are ‘natural derivatives’. This
distinction is artificial. Both tri-hybrid cells and SC-β cells are
created through controlled laboratory interventions that cannot and
do not occur in nature. The Court held that Section 3(j) of the Act
exclusion must be narrowly construed, and man-made cellular
constructs fall outside its scope. The same reasoning squarely
applies here.
Signed By:NEELAM
SHARMA
17:52:11
C.A.(COMM.IPD-PAT) 493/2022
8.3.
The Respondent misreads Section 3(j) of the Act. The exclusion
applies to “plants and animals in whole or any part thereof... and
essentially biological processes.” The claimed SC-β cells are not
whole animals, nor natural parts thereof, nor are they generated by
essentially biological processes. Instead, they are the product of a
multi-step laboratory-directed differentiation process.
8.4.
The Respondent invokes the decision in Association for
Molecular Pathology (supra) to argue that isolated natural
material is not patentable. However, in the said case, itself drew a
distinction between isolated DNA (unpatentable) and cDNA
(patentable) because cDNA is man-made. SC-β cells are analogous
to cDNA; they do not exist in nature and are generated only
through human intervention.
8.5.
The Respondent incorrectly asserts that derivation from pluripotent
stem cells renders the claimed cells ‘natural’. On the contrary, the
process of re-programming and differentiating stem cells into β
cells is an artificial, multi-stage laboratory protocol involving
growth factors, culture conditions, and gene regulation. This
process
is
neither
essentially
biological
nor
a
natural
developmental event. The mere use of a natural starting material
does not bar patentability of a novel, non-naturally occurring
product obtained therefrom.
8.6.
The SC-β cells developed by the Appellant are not the same as
natural β cells. They show special features that natural β cells do
not have such as different gene activity, better response to glucose,
and consistent production of only insulin. Something that has new
Signed By:NEELAM
SHARMA
17:52:11
C.A.(COMM.IPD-PAT) 493/2022
and different characteristics created by human effort is considered
an invention and not just a natural product. Reliance was placed
upon the decision in Sidney A. Diamond, Commissioner of
Patents and Trademarks v. Ananda M. Chakrabarty et al., 1980
SCC OnLine US SC 128 while making the above submission.
8.7.
The Respondent’s emphasis on use of embryonic / foetal material
is misplaced. The claims encompass derivation from induced
pluripotent stem cells, adult stem cells, and cadaveric sources,
which do not involve embryo destruction. The specification itself
clarifies that embryos were not destroyed.
8.8.
The Respondent relies upon the Department for Promotion of
Industry and Internal Trade notes regarding exclusion of ‘plants
and seeds’ to extend the exclusion to SC-β cells. Section 3(j) of the
Act primarily addresses plant / animal varieties and biological
propagation. Synthetic, engineered cellular products such as SC-β
cells are outside its ambit, consistent with international patent
practice where identical claims have been granted.
8.9.
The Respondent dismisses international grants as irrelevant,
however, Indian Courts, including in BTS Research International
(supra), have recognized that while foreign practice is not binding,
it is persuasive, especially when consistent across multiple major
jurisdictions. The uniform recognition of such inventions as
patentable supports the Appellant’s position.
8.10. The Respondent’s attempt to characterize non-native SC-β cells as
‘natural parts of animals’ is legally and scientifically untenable.
The claimed SC-β cells consistently show stable and distinct gene
Signed By:NEELAM
SHARMA
17:52:11
C.A.(COMM.IPD-PAT) 493/2022
expression patterns, superior insulin secretion, and glucose
responsiveness, distinguishing them from any naturally occurring
β cells. These reproducible differences demonstrate that the SC-β
cells are not mere natural variants, but a new and distinct cellular
construct created through human technical intervention. The
present invention represents a man-made construct (non-native),
not an essentially biological process or natural material. Thus, the
claims fall outside Section 3(j) of the Act and are patent-eligible.
ANALYSIS AND FINDINGS
9.
The present invention of Subject Application relates to “SC-β Cells,
Compositions and Methods for Generating the same.” As per the Abstract of
the Complete Specification, it discloses methods, compositions, kits, and
agents useful for inducing β cell maturation as well as isolated populations
of SC-β cells for use in various applications like cell therapy.
10.
The Complete Specification notes that the research to-date has
generated only abnormally functioning insulin-expressing cells that fails to
secrete appropriate amounts of insulin in response to sequentially varied
glucose levels / pancreatic progenitor cells which can only mature into
functioning insulin-expressing cells after three months of transplantation
into a mouse host. Contrary to normal islets / dispersed adult β cells, which
release high levels of insulin in response to high levels of glucose in the
glucose stimulated insulin secretion (“GSIS”) assay and can do so
repeatedly, human pluripotent stem cell derived insulin-expressing cells
which are generated by existing methods does not secrete insulin
appropriately in response to the addition of various concentrations of
glucose. Therefore, as per the Complete Specification of the Subject
Signed By:NEELAM
SHARMA
17:52:11
C.A.(COMM.IPD-PAT) 493/2022
Application, there is a need for a method of deriving cells from human
pluripotent stem cells which exhibit a phenotype of normal islets or mature
adult β cells.
11.
The present invention claims a non-native pancreatic β cell that
comprises one or more crystalline insulin granules. Claim no. 1 also claims
the non-native pancreatic β cell expressing the genes INS, PDX1, NKX6-1,
and ZNT8. This claim further claims the non-native pancreatic β cell which
exhibits an in vitro GSIS response to a first glucose challenge as well as
non-native pancreatic β cell that does not express one or both of
somatostatin and glucagon. The claims of the Subject Application are
reproduced hereunder:
“We Claim;
1. A composition comprising a non-native pancreatic β cell, and
one or more pharmaceutically acceptable carriers, additives, and/or
diluents, wherein:
(a) the non-native pancreatic β cell comprises one or more
crystalline insulin granules;
(b) the non-native pancreatic β cell expresses the following genes:
INS, PDX1, NKX6-1, and ZNT8;
(c) the non-native pancreatic β cell exhibits an in vitro glucose
stimulated insulin secretion (GSIS) response to a first glucose
challenge; and
(d) the non-native pancreatic β cell does not express one or both of
somatostatin and glucagon; and wherein said composition is in the
form of an in vitro cell cluster.
2. The composition as claimed in claim 1, wherein the non-native
pancreatic β cell exhibits an in vitro glucose-stimulated insulin
secretion response to a first glucose challenge, a second glucose
challenge, and a third glucose challenge, when the first glucose
challenge, the second glucose challenge and the third glucose
challenge are applied sequentially.
3. The composition as claimed in claim 1, wherein the non-native
pancreatic β cell further expresses at least one gene selected from
the group consisting of MAFA, PAX6, NEUROD1, GCK, SLC2A1,
PCSK1, KCNJ11, ABCC8, SNAP25, RAB3A, GAD2, PTPRN,
Signed By:NEELAM
SHARMA
17:52:11
C.A.(COMM.IPD-PAT) 493/2022
NKX2-2, and PAX4.
4. The composition as claimed in claim 1, wherein the non-native
pancreatic β cell secretes insulin in response to a first glucose
concentration compared to a second glucose concentration in a
ratio of at least 1.1 wherein the first glucose concentration is higher
than the second glucose concentration.
5. The composition as claimed in claim 1, wherein the non-native
pancreatic β cell is monohormonal.
6. The composition as claimed in claim 1, wherein the insulin
secreted by the nonnative pancreatic β cell is at least 0.5 μIU per
1000 cells per 30minute incubation when the non-native pancreatic
β cell is exposed to at least 20mM of glucose.
7. The composition as claimed in claim 1, wherein insulin secretion
from the nonnative pancreatic β cell is enhanced in response to an
anti-diabetic agent.
8. The composition as claimed in claim 1, wherein the non-native
pancreatic β cell exhibits cytokine-induced apoptosis in response to
a cytokine.
9. The composition as claimed in claim 1, wherein the non-native
pancreatic β cell has a gene expression profile that is different from
the gene expression profile of a native β cell.
10. An isolated population of cells comprising one or more nonnative pancreatic β cells as claimed in claim 1, wherein at least 10%
of the cells in the population of cells are the non-native pancreatic β
cells.
11. The population of cells as claimed in claim 10, further
comprising insulin positive endocrine cells.
12. The population of cells as claimed in claim 10, wherein the
population of cells comprises one of the following:
a. a C-peptide-negative/glucagon-positive cell;
b. a C-peptide -negative/somatostatin-positive cell;
c. a glucagon-positive/somatostatin-negative cell;
d. a glucagon-negative/somatostatin-positive cell; or
e. any combination thereof.
13. The population of cells as claimed in claim 10, wherein at least
3% of the population of cells are C-peptide –negative/glucagonpositive cells or glucagon positive/ somatostatin-negative cells.
14. An artificial islet comprising the population of cells as claimed
in claim 10.
15. An artificial pancreas comprising the population of cells as
claimed in claim 10.
Signed By:NEELAM
SHARMA
17:52:11
C.A.(COMM.IPD-PAT) 493/2022
12.
The learned Counsel for the Appellant filed the following amended
claims with the post-hearing Written Submissions to the learned Controller.
The claims are reproduced hereunder:
“We Claim,
1. A non-native pancreatic β cell, wherein:
(a) the non-native pancreatic β cell comprises one or more
crystalline insulin granules;
(b) the non-native pancreatic β cell expresses the following
genes: INS, PDX1, NKX6-1, and ZNT8;
(c) the non-native pancreatic β cell exhibits an in vitro
glucose stimulated insulin secretion (GSIS) response to a first
glucose challenge; and the non-native pancreatic β cell does
not express one or both of somatostatin and glucagon.
2. The non-native pancreatic β cell as claimed in claim 1, wherein
the non-native pancreatic β cell exhibits an in vitro glucosestimulated insulin secretion response to a first glucose challenge, a
second glucose challenge, and a third glucose challenge, when the
first glucose challenge, the second glucose challenge and the third
glucose challenge are applied sequentially.
3. The non-native pancreatic β cell as claimed in claim 1, wherein
the non-native pancreatic β cell further expresses at least one gene
selected from the group consisting of MAFA, PAX6, NEUROD1,
GCK, SLC2A1, PCSK1, KCNJ11, ABCC8, SNAP25, RAB3A, GAD2,
PTPRN, NKX2-2, and PAX4.
4. The non-native pancreatic β cell as claimed in claim 1, wherein
the non-native pancreatic β cell secretes insulin in response to a first
glucose concentration compared to a second glucose concentration
in a ratio of at least 1.1 wherein the first glucose concentration is
higher than the second glucose concentration.
5. The non-native pancreatic β cell as claimed in claim 1, wherein
the non-native pancreatic β cell is monohormonal.
6.The non-native pancreatic β cell as claimed in claim 1, wherein
the insulin secreted by the non-native pancreatic β cell is at least 0.5
μIU per 1000 cells per 30 minute incubation when the non-native
pancreatic β cell is exposed to at least 20mM of glucose.
7. The non-native pancreatic β cell as claimed claim 1, wherein
insulin secretion from the non-native pancreatic β cell is enhanced
in response to an antidiabetic agent.
8. The non-native pancreatic β cell as claimed in claim 1, wherein
the non-native pancreatic β cell exhibits cytokine-induced apoptosis
Signed By:NEELAM
SHARMA
17:52:11
C.A.(COMM.IPD-PAT) 493/2022
in response to a cytokine.
9. The non-native pancreatic β cell as claimed in claim 1, wherein
the non-native pancreatic β cell has a gene expression profile that is
different from the gene expression profile of a native β cell.
10. An isolated population of cells comprising one or more nonnative pancreatic β cells as claimed in claim 1, wherein at least
10% of the cells in the population of cells are the non-native
pancreatic β cells.
11. The population of cells as claimed in claim 10, further
comprising insulin positive endocrine cells.
12. The population of cells as claimed in claim 10, wherein the
population of cells comprises one of the following:
a. a C-peptide-negative/glucagon-positive cell;
b. a C-peptide -negative/somatostatin-positive cell;
c. a glucagon-positive/somatostatin-negative cell;
d. a glucagon-negative/somatostatin-positive cell; or
e. any combination thereof.
13. The population of cells as claimed in claim 10, wherein at least
3% of the population of cells are C-peptide –negative/glucagonpositive cells or glucagon positive/ somatostatin-negative cells.
14. An artificial islet comprising the population of cells as claimed
in claim 10.
15. An artificial pancreas comprising the population of cells as
claimed in claim 10.”
13.
A perusal of the Impugned Order reveals that the learned Controller
has based the finding while considering the original claims. Although the
Impugned Order has mentioned the amended claims placed on record
through the post-hearing Written Submissions as “Alternative set of
Claims”, the same are not considered while passing the Impugned Order.
14.
It is clear from the amended claims that they are not composition
claims as evident from the comparison of original claim no. 1 and amended
claim no. 1, which are reproduced hereunder:
Signed By:NEELAM
SHARMA
17:52:11
C.A.(COMM.IPD-PAT) 493/2022
Original claim no. 1
Amended claim no. 1
1. A composition comprising a non- 1. A non-native pancreatic β
native pancreatic β cell, and one or cell, wherein:
more pharmaceutically acceptable
(a)
the
non-native
carriers, additives, and/or diluents,
pancreatic β cell comprises
wherein:
one or more crystalline
(a) the non-native pancreatic
insulin granules;
P cell comprises one or more
(b)
the
non-native
crystalline insulin granules;
pancreatic β cell expresses
(b) the non-native pancreatic p
the following genes: INS,
cell expresses the following
PDX1, NKX6-1, and ZNT8;
genes: INS, PDX 1, NKX6-1,
(c)
the
non-native
and ZNT8;
pancreatic β cell exhibits an
(c) the non-native pancreatic
in vitro glucose stimulated
P cell exhibits an in vitro
insulin secretion (GSIS)
glucose stimulated insulin
response to a first glucose
secretion (GSIS) response to a
challenge; and the nonfirst glucose challenge; and
native pancreatic β cell
(d) the non-native pancreatic p
does not express one or
cell does not express one or
both of somatostatin and
both of somatostatin and
glucagon.
glucagon; and wherein said
composition is in the form of
an in vitro cell cluster”
15.
As the Impugned Order has only considered the original claims and
not the amended claims filed along the post-hearing Written Submissions, it
would be imperative to examine the impact of the amended claims on the
Subject Application. The Impugned Order has, under Objection Nos. 1 and
5, considered the original claims and held that the technical disclosure is
missing in the claimed composition and, therefore, the objections under
Sections 10(4) and 10(5) of Act continued to subsist.
16.
As regards the objections under Sections 3(j) and 3(e) of the Act, the
Impugned Order again considers the original claims and it is concluded that
the Complete Specification neither discloses a composition per se, nor does
it disclose all the components or their amounts or synergy data. However, if
Signed By:NEELAM
SHARMA
17:52:11
C.A.(COMM.IPD-PAT) 493/2022
the amended claims are considered, they claim a non-native pancreatic β cell
instead of the composition in the original claims. Therefore, the entire basis
of the Impugned Order may undergo change if the amended claims are
considered by the learned Controller.
17.
In Jitendra Kohli v. The Controller of Patents, Neutral Citation:
2022:DHC:1904, the Court held that not considering the amended claims is
clearly a glaring error. The relevant paragraphs are reproduced hereunder:
“8. The Court has perused the entire order which clearly shows that
the Assistant Controller has considered the invention to be a
computer based realization of a conventional bidding process
method of doing business. The Assistant Controller has come to the
conclusion that the technical advance proposed in the invention is
simply a method of doing business, even if it is a technically smarter
way of doing business and has rejected the application under
Section 3(k) of the Act. The amended claims have not been taken into
consideration by the Assistant Controller at the time of deciding the
fate of Appellant's application. This is clearly a glaring error.
*** *** ***
10. Under these circumstances, the impugned order is set aside. The
matter shall be reconsidered by the office of Controller General of
Patents, Designs, & Trade Marks (CGPDTM) afresh. A fresh order
shall be passed after duly considering the amended claims on all
counts including novelty, inventive step and patentability.”
18.
Further, in Akebia Therapeutics INC v. The Controller of Patents
and Designs, CMA(PT)/64/2024 dated 20.03.2025, the Court held that the
amended claims change the nature of the claims from method to
composition claims and, therefore, it becomes crucial for the controller to
address the same. The relevant paragraphs are reproduced hereunder:
“9. In effect, the respondent has rejected the claim substantially, if
not entirely, on the ground that the appellant has amended the claim
from a claim for a method of treating anaemia to a claim for a
pharmaceutical composition which may be used for treating
anaemia. As held in Allergan and concurred by me in an earlier
decision in Commonwealth Scientific & Industrial Research
Signed By:NEELAM
SHARMA
17:52:11
C.A.(COMM.IPD-PAT) 493/2022
Organization and Anr. v. The Assistant Controller of Patents &
Designs 2023/MHC/4501, the rejection substantially or solely on
such ground is not tenable. On comparing the original claims with
the amended claims, I find that the scope of the claims remains the
same, but the nature of the claims have changed from method to
composition claims. Since objections were also raised on grounds of
lack of inventive step and with reference to Sections 3(i) and 3(e),
and those aspects were not discussed or determined in the impugned
order, a remand is necessary.
10. Therefore, impugned order dated 26.11.2021 is set aside and the
matter is remanded for re-consideration on the following terms:
(i) In order to preclude the possibility of pre determination,
an officer other than the officer who issued the impugned
order shall undertake re-consideration.
(ii) After providing a reasonable opportunity to the
appellant, a reasoned decision shall be issued within a
period of four months from the date of receipt of a copy of
this order.
(iii) For the avoidance of doubt, it is made clear that no
observation has been made on the merits of the patent
application.”
19.
Consequently, amended claims that significantly alter the original
claims transitioning from a composition to a non-native pancreatic β cell
must be duly considered by the learned Controller independently without
being influenced from prior conclusions regarding the original claims in the
Impugned Order. Accordingly, the Impugned Order is hereby set aside, and
the matter is remanded back to the learned Controller for fresh consideration
of the Subject Application in view of the amended claims submitted along
with post-hearing Written Submissions. This learned Controller shall pass a
detailed order on the Subject Application after considering the amended
Claims within six months from the date of communication of this Judgment
after giving opportunity of hearing to the Appellant.
20.
It is clarified that this Court has not considered the merits of the
respective cases, and the Subject Application shall be decided in accordance
Signed By:NEELAM
SHARMA
17:52:11
C.A.(COMM.IPD-PAT) 493/2022
with law without being influenced by any observations made in this
Judgement. Accordingly, the Appeal is disposed of with the aforesaid
directions.
21.
A copy of this Judgement be sent to the learned Controller General of
Patents, Designs and Trademarks at the e-mail address llc-ipo@gov.in for
the necessary compliance.
TEJAS KARIA, J
MARCH 28, 2026
‘KC’ / ‘N’
Signed By:NEELAM
SHARMA
17:52:11
C.A.(COMM.IPD-PAT) 493/2022
This page is for informational and research purposes only and does not constitute legal advice.
Consult a qualified advocate for advice specific to your situation.
Is your name in this judgment and should it be masked, or is something on this page wrong?
Request a review